Does NeoGenomics (NASDAQ:NEO) Have A Healthy Balance Sheet?
NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Needham analyst Michael Matson maintains $NeoGenomics(NEO.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 43.6% and a
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $NeoGenomics(NEO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.6% and a total average return of -3.9% over the
Craig-Hallum Remains a Buy on NeoGenomics (NEO)
Benchmark Reiterates Buy on NeoGenomics, Maintains $18 Price Target
NeoGenomics Analyst Ratings
Benchmark Co. Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $18
Benchmark Co. analyst Bruce Jackson maintains $NeoGenomics(NEO.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 31.2% and a
Analysts Conflicted on These Healthcare Names: American Well (AMWL), Cogent Biosciences (COGT) and NeoGenomics (NEO)
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
Express News | Neogenomics Announces New Radar Technology and Resolution of Radar 1.0 Litigation
Express News | Natera: Seeks Full Remedies, After Patent Office Denied Neogenomics' Petition for 'inter Partes' Review Challenging Validity of '454 Patent
Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of CtDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
NeoGenomics (NASDAQ:NEO Shareholders Incur Further Losses as Stock Declines 3.2% This Week, Taking Three-year Losses to 69%
Express News | Neogenomics Inc : Piper Sandler Raises Target Price to $21 From $20
Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?